The global Edward’s syndrome treatment market is expected to garner a market value of US$ 4.9 Billion in 2023 and is expected to accumulate a market value of US$ 7.98 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The growth of Edward’s syndrome treatment market can be attributed to an increase in investment in research and development. The market for Edward’s syndrome registered a CAGR of 3% in the historical period 2018 to 2022
Edwards syndrome, also known as Trisomy 18, is a chromosomal disorder that occurs in about 1 in 5,000 live births. The condition is characterized by severe intellectual disability and physical abnormalities, and many affected infants do not survive beyond the first few months of life.
It is possible that with the advancement of medical technology, doctors are now able to diagnose Edwards syndrome more accurately and earlier in pregnancy, which may lead to an increase in demand for treatment. Additionally, with the increasing popularity of genetic testing, more families may be learning about the diagnosis in their family, leading to more demand for treatment.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.9 Billion |
| Anticipated Forecast Value (2033) | US$ 7.98 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Edward’s syndrome treatment reflected a value of 3% during the historical period, 2018 to 2022.
Treatment for Edwards syndrome focuses mainly on addressing the symptoms and complications that result from the condition. There is no cure for Edwards syndrome, and treatment is supportive in nature. It usually involves a team of healthcare professionals such as physicians, nurses, genetic counselors, occupational therapists, physical therapists, speech therapists, and social workers to provide comprehensive care. The focus is on providing medical care and support to the affected individual and their families in order to improve their quality of life. Treatments may include surgery, physiotherapy, speech therapy, and support for developmental milestones.
Thus, the market for Edward’s syndrome treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Improved healthcare infrastructure and government initiatives supporting market growth
The rapid rise in cases of central nervous system disorder is expected to accelerate the market growth in the forecast period of 2023 to 2033. Likewise, the increase in the occurrence of Edwards syndrome and rise in the healthcare spending is also predictable to enhance the Edwards syndrome treatment market growth. Furthermore, the increased government support and the rise in genetic counseling are also projected to drive the market growth rate.
In addition, the technological advancements for effective treatment and the easy availability of advanced healthcare facilities are likely to create various new opportunities that will impact this Edwards syndrome market growth in the forecast period of 2023 to 2033.
The availability of various treatments creates lucrative opportunities for the Edwards syndrome market
Treatment for Edwards syndrome primarily focuses on managing the symptoms and complications that arise from the condition.
Prenatal care: when a fetus is diagnosed with Edwards syndrome, regular prenatal care can help monitor the baby's growth and development, as well as prepare for the delivery and care of the baby after birth.
Medical management: infants with Edwards syndrome often have a range of medical issues that need to be addressed, such as heart defects, respiratory problems, and feeding difficulties. Treatment may involve surgery, medication, and other therapies to address these issues.
Supportive care: infants with Edwards syndrome will require extensive care and support to address their physical and intellectual disabilities. This may include physical therapy, occupational therapy, speech therapy, and other forms of rehabilitation to help them reach their full potential.
Genetic counseling: for families who have a child with Edwards syndrome, genetic counseling may be recommended to help them understand the condition and the risks of recurrence in future
Principal Consultant
Lack of awareness and failure of treatment hindering the overall market growth
The high treatment cost and lack of awareness about the treatment are expected to act as major restraints towards the growth of the Edwards syndrome market, whereas lack of awareness amongst patients can challenge the growth of the target market in the above-mentioned forecast period.
Certain treatments may improve some of the symptoms, but they do not cure the underlying genetic problem. Even with the best care, most infants with Edwards syndrome do not survive past their first year of life. Thus, all these factors are hampering the growth of the overall market.
Government-based foundations help families to understand Edwards syndrome better
In North America prenatal screening is offered to all pregnant women as part of their routine care. The screening allows for the identification of fetuses at increased risk of chromosomal disorders such as Edward syndrome, where then follow-up diagnostic tests, such as chorionic villus sampling or amniocentesis, can confirm or exclude the diagnosis. With the advancement of prenatal screening and diagnostic technologies, doctors are now able to diagnose Edwards syndrome more accurately and earlier in pregnancy which could lead to an increase in demand for treatment.
It's worth mentioning that, in North America, there are also a number of organizations that provide support and resources for families affected by Edwards syndrome, such as the Trisomy 18 Foundation. These organizations can help families connect with others who have experience with the condition, learn about treatments and resources, and advocate for their loved one's care.
Thus, North America is expected to possess a 45% market share of the Edwards syndrome treatment market in 2023.
Integration of technology offering better results for diagnostic tests
Healthcare systems and resources vary greatly across the countries and regions of Asia Pacific, especially in China, India, and Japan. This, in turn, has created wide availability and accessibility of treatments for Edwards syndrome in the region. With increasing access to better healthcare resources and genetic screening techniques, the diagnostics and treatments for Edwards Syndrome are expected to improve in the region.
Furthermore, the presence of well-developed healthcare infrastructure and favorable government support. Thus, Asia Pacific is expected to hold a 39% market share for Edwards syndrome treatment in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end-user, the Edwards syndrome treatment market is segmented into Hospitals, Clinics, Ambulatory Surgical Centres, Others
The hospital segment is expected to hold the largest market share for Edward’s syndrome treatment. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of Edward’s syndrome treatment.
Furthermore, initiatives by government authorities to support the treatment of Edward’s syndrome treatment, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Edward’s syndrome treatment. Thus, hospitals are expected to hold a 40% market share of Edward’s syndrome treatment market in 2023.
Key players in the Edwards syndrome treatment market are Merck & Co, Kyorin Pharmaceuticals, Pfizer Inc, Bellus Health, Eli Lilly and Company, GeneScience Pharmaceuticals Co., Ltd, Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd, Sanofi, Bayer AG
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.9 Billion |
| Market Value in 2033 | US$ 7.98 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The Edward’s syndrome treatment market is expected to garner a market value of US$ 4.9 Billion in 2023.
India, Japan, and China dominate the Asian market.
Improved healthcare infrastructure and the availability of various treatments drive market growth.
The hospital segment is expected to lead the market.
The high treatment cost and lack of awareness about the treatment limits the growth potential.
1. Executive Summary | Edward’s Syndrome Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By Types
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Types, 2018-2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Types, 2023 to 2033
5.3.1. Full Trisomy 18
5.3.2. Mosaic Trisomy 18
5.3.3. Partial Trisomy 18
5.4. Y-o-Y Growth Trend Analysis By Types, 2018-2022
5.5. Absolute $ Opportunity Analysis By Types, 2023 to 2033
6. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018-2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Cardiac Treatment
6.3.2. Assisted Feeding
6.3.3. Orthopaedic Treatment
6.3.4. Psychosocial Support
6.3.5. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By End-user
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018-2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Ambulatory Surgical Centres
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-user, 2018-2022
7.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033
8. Global Market Analysis 2018-2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018-2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Types
9.2.3. By Treatment
9.2.4. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Types
9.3.3. By Treatment
9.3.4. By End-user
9.4. Key Takeaways
10. Latin America Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Types
10.2.3. By Treatment
10.2.4. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Types
10.3.3. By Treatment
10.3.4. By End-user
10.4. Key Takeaways
11. Europe Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Types
11.2.3. By Treatment
11.2.4. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Types
11.3.3. By Treatment
11.3.4. By End-user
11.4. Key Takeaways
12. South Asia Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Types
12.2.3. By Treatment
12.2.4. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Types
12.3.3. By Treatment
12.3.4. By End-user
12.4. Key Takeaways
13. East Asia Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Types
13.2.3. By Treatment
13.2.4. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Types
13.3.3. By Treatment
13.3.4. By End-user
13.4. Key Takeaways
14. Oceania Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Types
14.2.3. By Treatment
14.2.4. By End-user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Types
14.3.3. By Treatment
14.3.4. By End-user
14.4. Key Takeaways
15. MEA Market Analysis 2018-2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Types
15.2.3. By Treatment
15.2.4. By End-user
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Types
15.3.3. By Treatment
15.3.4. By End-user
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Types
16.1.2.2. By Treatment
16.1.2.3. By End-user
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Types
16.2.2.2. By Treatment
16.2.2.3. By End-user
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Types
16.3.2.2. By Treatment
16.3.2.3. By End-user
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Types
16.4.2.2. By Treatment
16.4.2.3. By End-user
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Types
16.5.2.2. By Treatment
16.5.2.3. By End-user
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Types
16.6.2.2. By Treatment
16.6.2.3. By End-user
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Types
16.7.2.2. By Treatment
16.7.2.3. By End-user
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Types
16.8.2.2. By Treatment
16.8.2.3. By End-user
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Types
16.9.2.2. By Treatment
16.9.2.3. By End-user
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Types
16.10.2.2. By Treatment
16.10.2.3. By End-user
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Types
16.11.2.2. By Treatment
16.11.2.3. By End-user
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Types
16.12.2.2. By Treatment
16.12.2.3. By End-user
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Types
16.13.2.2. By Treatment
16.13.2.3. By End-user
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Types
16.14.2.2. By Treatment
16.14.2.3. By End-user
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Types
16.15.2.2. By Treatment
16.15.2.3. By End-user
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Types
16.16.2.2. By Treatment
16.16.2.3. By End-user
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Types
16.17.2.2. By Treatment
16.17.2.3. By End-user
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Types
16.18.2.2. By Treatment
16.18.2.3. By End-user
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Types
16.19.2.2. By Treatment
16.19.2.3. By End-user
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Types
16.20.2.2. By Treatment
16.20.2.3. By End-user
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Types
16.21.2.2. By Treatment
16.21.2.3. By End-user
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Types
17.3.3. By Treatment
17.3.4. By End-user
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Merck & Co
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Kyorin Pharmaceuticals
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Pfizer Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Bellus Health
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Eli Lilly and Company
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. GeneScience Pharmaceuticals Co., Ltd.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Johnson & Johnson Private Limited
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Teva Pharmaceutical Industries Ltd.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Sanofi
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Bayer AG
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Edward’s Syndrome Treatment Market
